Jawline filler passes safety check in 114-Person trial

NCT ID NCT06562075

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety and effectiveness of Decoria Intense Strong, a filler used to improve the shape of the jawline. 114 adults received the treatment. Doctors found that it safely enhanced jawline contour, with most patients showing noticeable improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

114 people

The number who actually took part.

Started

Sep 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults ≥18 years, males and females. 2. Able and willing to give written informed consent for participation in the investigation. 3. Treating investigator considers the subject's jaw (including or not including chin) amenable to an improvement of at least 1 grade on GAIS. At least one side with either potential to enhance contouring or moderate to severe loss of jawline definition. The grades do not have to be the same on both sides. 4. Ability to follow study instructions and likely to complete all required visits. Exclusion Criteria: 1. Pregnant or lactating females. 2. Any previous hypersensitivity reaction to any constituent of the Investigational medical device (IMD) or to local anesthetic products. 3. Performed or planned surgery below the nose, permanent implant, injection with fat, and deoxycholic acid that may confound the evaluation of safety and performance of the IMD. 4. Any other intradermal injection, such as semi-permanent fillers or botulinum toxins (no complications are allowed), received in the same injection area within 9 months of the Treatment visit (Visit 1) that may confound the evaluation of safety and performance of the IMD. 5. Has an ongoing episode/relapse, recently diagnosed or newly started medication of an autoimmune disease, as judged by the investigator. 6. Has any chronic or acute skin disease or inflammation (such as pimples, rashes or hives) within or close to the treatment area. 7. Has any treatments (thrombolytics, anticoagulants etc) or disease related to the coagulation system. 8. Subjects that have taken any type of vaccine within two weeks prior injection with the IMD. 9. Patients receiving interferon and ribavirin treatment. 10. Features that may interfere with the visual assessment such as recent cosmetic treatment, scarring, abscess, piercing or tattoo. 11. Participation in a clinical investigation that may affect the safety or performance of this investigation, as judged by the Principal Investigator, or authorized designee. 12. Employees of the study site or the sponsor directly involved with the conduct of the investigation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Jawline contour deficit are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Florakliniken

    Stockholm, 113 28, Sweden

  • Göteborg Laser & Estetik

    Gothenburg, 411 08, Sweden

  • Inskinity

    Gothenburg, 411 07, Sweden

  • Inskinity

    Stockholm, 111 28, Sweden

  • Svenska Hudkliniker

    Karlstad, 652 25, Sweden

  • Svenska Hudkliniker

    Stockholm, Sweden

  • The Faculty

    Stockholm, 114 46, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.